Epigenetic derepression converts PPARγ into a druggable target in triple-negative and endocrine-resistant breast cancers

Epigenetic derepression converts PPARγ into a druggable target in triple-negative and endocrine-resistant breast cancers

Abstract Clinical trials repurposing peroxisome proliferator-activated receptor-gamma (PPARγ) agonists as anticancer agents have exhibited lackluster efficacy across a variety of tumor types. Here, we report that increased PPARG expression is associated with a better prognosis but is anticorrelated...

Full description

Bibliographic Details
Main Authors: Ser Yue Loo, Nicholas L. Syn, Angele Pei-Fern Koh, Janet Cheng-Fei Teng, Amudha Deivasigamani, Tuan Zea Tan, Aye Aye Thike, Shireen Vali, Shweta Kapoor, Xiaoyuan Wang, Jiong Wei Wang, Puay Hoon Tan, George W. Yip, Gautam Sethi, Ruby Yun-Ju Huang, Kam Man Hui, Lingzhi Wang, Boon Cher Goh, Alan Prem Kumar
Format: Article
Language:English
Published: Nature Publishing Group 2021-09-01
Series:Cell Death Discovery
Online Access:https://doi.org/10.1038/s41420-021-00635-5

Internet

https://doi.org/10.1038/s41420-021-00635-5

Similar Items